Voyager Therapeutics, Inc. — Q3 2016 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2016. Financial statements are unaudited; amounts below are in millions of dollars except per-share data.
Business context
Voyager is a clinical-stage gene-therapy company developing AAV-based treatments for central nervous system diseases. It has no approved products and generated no product sales; reported revenue came from its Genzyme collaboration. Its lead candidate, VY-AADC01, was in an open-label Phase 1b trial for advanced Parkinson’s disease, with human proof-of-concept data targeted for early December 2016. The company also expected to file an IND for its ALS program, VY-SOD101, in late 2017.
Key financial metrics
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Collaboration revenue | $3.3 | $4.9 | $11.9 | $12.4 |
| Research and development expense | $10.3 | $6.5 | $29.5 | $18.5 |
| General and administrative expense | $3.4 | $2.5 | $9.8 | $6.8 |
| Operating loss | ($10.4) | ($4.0) | ($27.5) | ($12.8) |
| Net loss | ($9.0) | ($3.9) | ($25.5) | ($22.4) |
| Operating cash flow | Not separately presented | Not separately presented | ($29.4) | $50.9 |
Q3 operating margin was approximately negative 314% of collaboration revenue; the company remained loss-making. Q3 revenue fell about 33% year over year while R&D expense rose about 59%. For the nine-month period, revenue declined about 4%, R&D expense increased about 60%, and net loss increased about 14%. The 2015 nine-month comparison includes $9.75 million of expense from remeasuring preferred-stock tranche rights, making the reported net-loss comparison less directly comparable.
At September 30, cash and cash equivalents were $63.5 million; marketable debt securities were $127.6 million, for reported cash, cash equivalents and marketable debt securities of $191.2 million. Total assets were $202.0 million, total liabilities $52.9 million, and stockholders’ equity $149.1 million. No interest-bearing debt was reported. Deferred revenue was $43.8 million, reflecting unearned collaboration consideration. The company stated that its available funds were expected to support its current operating plan into 2019, subject to execution and other uncertainties.
Nine-month investing cash flow was positive $61.4 million, principally reflecting $129.7 million of security maturities, partly offset by $66.6 million of security purchases and $1.2 million of property and equipment purchases. Financing cash flow was $0.1 million, mainly from stock-option exercises. The 2015 operating cash inflow included Genzyme’s $65.0 million upfront payment.
Material changes and unusual items
- Higher R&D spending reflected increased headcount, third-party research and development, manufacturing preparation, and facility costs. G&A also rose, primarily with staffing and public-company costs.
- Genzyme collaboration revenue was reduced by an estimated $1.2 million per quarter after extending the expected service period for two accounting units, and by $0.5 million in Q3 after lowering estimates of Genzyme in-kind services.
- Q3 other income included an approximately $0.8 million mark-to-market gain on warrants received in connection with the MRI Interventions investment, as well as higher interest income.
- In September 2016, Voyager paid $2.0 million for MRI Interventions common stock and a warrant, purchased about $0.3 million of supplies, and could be obligated to purchase another $1.0 million of stock upon completion of a technology transfer.
- Operating lease commitments totaled $30.1 million, including commitments associated with a facility expansion; the additional approximately 26,000-square-foot Cambridge space was expected to be ready for occupancy in early 2017.
Outlook, risks and contingencies
In November 2016, Voyager elected to deprioritize VY-SMN101 for spinal muscular atrophy, citing progress in other preclinical programs and the competitive landscape. The company said it expected to reassess related collaboration revenue recognition in Q4 and expected revenue to decrease.
Management expected R&D and operating losses to increase as programs advance, clinical studies proceed, and manufacturing capabilities are developed. The company may need substantial additional funding; financing may be unavailable or dilutive, and insufficient capital could force delays, reductions, or termination of programs. Key risks include clinical and regulatory failure, manufacturing scale-up, competition, intellectual-property protection, and dependence on collaboration partners. The Genzyme agreement provides for potential milestones of up to $645 million and royalties, but these depend on option exercises and future achievements and are not assured. Voyager reported no litigation or litigation reserves as of September 30, 2016, and stated that disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- Whether the VY-AADC01 trial produced the anticipated proof-of-concept data and how results affect development plans.
- The revised VY-SMN101 program status and the Q4 2016 effect of deprioritization on Genzyme collaboration revenue and deferred revenue.
- Whether the stated funding runway into 2019 remains supportable as clinical, R&D, facility, and manufacturing spending evolves.
- Progress and costs under the Genzyme collaboration, including option decisions, revenue-recognition estimates, and any milestone eligibility.
- Execution of the MRI Interventions technology transfer and any resulting additional stock-purchase obligation.